Peritoneal transfer of kanamycin and its use in peritoneal dialysis

Atkins, Robert C.; Mion, Charles; Despaux, Ernest; Van-Hai, Nguyen; Julien, Christian; Mion, Henri
January 1973
Kidney International;Jan1973, Vol. 3 Issue 1, p391
Academic Journal
The effect of kanamycin administration on 15 functionally anephric chronic renal failure patients undergoing maintenance peritoneal dialysis was studied. Following intramuscular administration of kanamycin (7 mg/kg body wt), peritoneal dialysis of 22 hr removed 32 % of the injected dose. The mean kanamycin peritoneal clearance was 8.3 ml/mm compared to a creatinine peritoneal clearance of 17.7 ml/mm, Peritoneal dialysis reduced the serum half-life of kanamycin from 84 to 12 hr. If an anuric patient receiving kanamycin therapy is undergoing peritoneal dialysis, then additional kanamycin amounting to about 3.5 mg/kg body wt for each day of peritoneal dialysis must be given to compensate for dialysis removal. However, compensation is more easily obtained by adding kanamycin to the inflow peritoneal dialysate. It reaches a therapeutic serum concentration following ten hr of dialysis and maintains a state of equilibrium after 16 hr, with the serum level approximately 50% of the dialysate inflow concentration. Thus a serum level can be maintained by adding twice the desired serum concentration to the peritoneal dialysate. In most cases addition of 20 mg of kanamycin to each liter of inflow dialysate is recommended.


Related Articles

  • Educating end-stage renal disease patients on dialysis modality selection. Covic, Adrian; Bammens, Bert; Lobbedez, Thierry; Segall, Liviu; Heimbürger, Olof; van Biesen, Wim; Fouque, Denis; Vanholder, Raymond // NDT Plus;Jun2010, Vol. 3 Issue 3, p225 

    The article presents clinical advice on renal replacement therapy (RRT) modality selection for end-stage renal disease (ESRD) patients issued by the European Renal Best Practice (ERBP) Expert Group. The initial modality choice is to be made by the patient, after being informed and based on what...

  • Role of peritoneal cavity lymphatic absorption in peritoneal dialysis. Mactier, Robert A.; Khanna, Ramesh; Twardowski, Zbylut J.; Nolph, Karl D. // Kidney International;Aug1987, Vol. 32 Issue 2, p165 

    Discusses the increasing number of patients with end-stage renal disease on peritoneal dialysis therapy. Role of lymphatic absorption from the peritoneal cavity; Occurrence of peritoneal cavity from end lymphatic located in the diaphragm; Assumptions affecting the measurement of the peritoneal...

  • Profiles of automated peritoneal dialysis prescriptions in the US 1997–2003. Mujais, S.; Childers, R. W. // Kidney International Supplement;Nov2006, Issue 103, pS84 

    Automated peritoneal dialysis (PD) is the dominant mode of delivery of PD in the US. Information about actual prescribing patterns has been limited. The present study examines cycler prescription use in large cohorts during the years 1997, 2000, and 2003. We observed trends consisting of...

  • Uremic Toxins and Lipases in Haemodialysis: A Process of Repeated Metabolic Starvation. Stegmayr, Bernd // Toxins;May2014, Vol. 6 Issue 5, p1505 

    Severe kidney disease results in retention of uremic toxins that inhibit key enzymes for lipid breakdown such as lipoprotein lipase (LPL) and hepatic lipase (HL). For patients in haemodialysis (HD) and peritoneal dialysis (PD) the LPL activity is only about half of that of age and gender matched...

  • Factores predictivos de disfunción en catéteres de Tenckhoff colocados en el Hospital Central Militar. Garduño-Manjarrez, Pedro; Cisneros-Vera, Dirta Del Carmen; Noyola-Villalobos, Héctor // Revista de Sanidad Militar;nov/dic2010, Vol. 64 Issue 6, p262 

    No abstract available.

  • Peritoneal Dialysis: Does It Have a Brighter Future? Mehrotra, Rajnish // Renal & Urology News;Nov2010, Vol. 9 Issue 11, p10 

    The article focuses on the peritoneal dialysis (PD) as a long-term treatment for PD patients. It states that since its application for the treatment of uremia is a failure, three major advances were made including an indwelling intraperitoneal catheter, and the description of constant...

  • Peritoneal dialysis catheter placement by interventional radiologists. Guest, Steven; Abdel Aal, Ahmed K. // Clinical Kidney Journal;Feb2014, Vol. 7 Issue 1, p1 

    The authors comments on the results of the research findings on the medical risks for peritoneal dialysis catheter placement in patient with peritoneal dialysis. One of the author's highlights the preventive health methods use treating kidney disease and emphasizes the importance of kidney...

  • Aluminum loading in children with chronic renal failure. Sedman, Aileen B.; Miller, Nancy L.; Warady, Bradley A.; Lum, Gary M.; Alfrey, Allen C. // Kidney International;Aug1984, Vol. 26 Issue 2, p201 

    Plasma aluminum levels were measured in 17 children with chronic renal failure who were receiving aluminum containing antacids for the control of hyperphosphatemia. Seven children were on hemodialysis, five on peritoneal dialysis, and five were awaiting dialysis with creatinine clearances...

  • Preservation of residual renal function in peritoneal dialysis patients: Still a dream? Locatelli, F.; La Milia, V. // Kidney International;Jan2008, Vol. 73 Issue 2, p143 

    The results of the randomized trial by Fan et al. suggest that ‘biocompatible’ peritoneal dialysis solutions have no major advantage over standard solutions in peritoneal dialysis patients in relation to residual renal function (RRF) and technique survival. The possible effect of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics